# A Clinical Study of TQB3824 in Subjects With Advanced Cancer

> **NCT05028218** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 65 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQB3824 tablets

## Key facts

- **NCT ID:** NCT05028218
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-31
- **Primary completion:** 2024-08
- **Final completion:** 2024-12
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028218, "A Clinical Study of TQB3824 in Subjects With Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05028218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*